Highlight
ASD-HIPROS
Find more about our Spray Drying screening service for poor soluble drugs
/products-and-services/contract-manufacturing-services/particle-engineering/development/asd-hiprosWho we are
Hovione is a Contract Development and Manufacturing Company dedicated to helping Pharmaceutical Customers bring new and off-patent drugs to market. We do well what is difficult, to give our customers what they cannot find elsewhere.
Highlight
Continuous Tableting for Drug Product
Go from development to manufacturing in record time with high quality and less variability
/products-and-services/contract-manufacturing-services/drug-product/continuous-tableting-drug-product
Highlight
One-Site Solution for Inhalation and Nasal
We live and breathe innovation for the successful delivery of your inhalation and nasal therapies.
https://www.hovione.com/products-and-services/contract-manufacturing-services/drug-product/inhalationWhat are we in it for?
Nurturing a strong quality culture that leads to safe medicines. The privilege of serving patients with uncompromising honesty, integrity and transparency. We are In it for life.
04/10/2023
online
Webinar: High performance solutions for DPI delivery: new formulation and device platforms
October 4th, 2023 11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT Registrations to the webinar are subject to approval. Register now! Featured Hovione experts in this webinar Susana Saldanha, M.Sc. R&D Manager, Inhalation and Advanced Drug Delivery Sofia Silva, M.Sc. R&D Manager, Analytical Development This webinar will address the most relevant solutions for dry powder inhaler (DPI) development covering both formulation and device development, as well as process optimization and analytical characterization, under an integrated development approach. DPIs are the dosage form of choice for delivering high doses of inhaled drugs and achieving maximum delivery efficiency to patients. This presentation will focus on new formulation platforms, aiming to address the pharmacokinetics requirements of the target drug and indication, coupled with a new high performance, high-dose device platform, the Sunriser® DPI. This integrated approach is designed to maximize drug delivery efficiency while maintaining safety, and is able to address a diversified array of diseases. Register Now! Key Learning Objectives: Gain insights on novel formulation development strategies for DPIs, to be able to improve drug delivery efficiency even with high drug loads; Understand the potential of wet milling and dry milling capabilities for boosting the fine particle dose of DPI formulations; Discover analytical characterization techniques, for differentiated formulations, to further understand product properties that impact drug delivery and aerodynamic performance; Understand features associated with a novel high efficiency device platform, the Sunriser® capsule-based Dry Powder Inhaler; Network with industry peers and experts during the live Q&A session. Who Should Attend: Pharmaceutical researchers and scientists CMC experts on inhalation drug delivery Business development, portfolio management and technology licensing experts Inhalation product development professionals Respiratory therapeutics specialists Register now and join us Our experts will reply to your questions during the live Q&A session.
News and media
Article
Article
Article